XML 48 R39.htm IDEA: XBRL DOCUMENT v3.26.1
Collaboration and License Agreements - Regeneron Pharmaceuticals, Inc - Additional Information (Details)
$ in Thousands
1 Months Ended
Nov. 16, 2022
USD ($)
Jul. 31, 2026
USD ($)
May 31, 2026
USD ($)
Target
Jun. 30, 2026
USD ($)
Dec. 31, 2025
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Deferred revenue       $ 54,690 $ 28,467 $ 32,291 $ 94,063
Regeneron Pharmaceuticals, Inc              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Number of targets selected | Target     2        
Deferred revenue       45,400      
Collaborative Arrangement | Regeneron Pharmaceuticals, Inc              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Right to expand the number of additional collaboration target | Target     8        
Upfront payment received $ 30,000   $ 37,000        
Collaboration and License Agreement | Regeneron Pharmaceuticals, Inc              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront payment received   $ 37,000 37,000        
Estimated research and development service fees     10,000        
Total transaction price     56,400        
Deferred revenue     9,400 45,400 10,500    
Amount due from customer       $ 37,500 $ 800    
Collaboration and License Agreement | Regeneron Pharmaceuticals, Inc | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent milestone payments receivable 800,000   800,000        
Additional milestone payment received $ 1,200,000            
Collaboration and License Agreement | Regeneron Agreement | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent milestone payments receivable     $ 4,000,000